company background image
NOVO B

Novo Nordisk CPSE:NOVO B Stock Report

Last Price

kr.897.30

Market Cap

kr.2.0t

7D

0.5%

1Y

19.5%

Updated

08 Dec, 2022

Data

Company Financials +
NOVO B fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance4/6
Financial Health4/6
Dividends3/6

NOVO B Stock Overview

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide.

Novo Nordisk A/S Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Novo Nordisk
Historical stock prices
Current Share Pricekr.897.30
52 Week Highkr.902.50
52 Week Lowkr.604.40
Beta0.34
1 Month Change5.48%
3 Month Change12.19%
1 Year Change19.51%
3 Year Change135.23%
5 Year Change166.74%
Change since IPO16,547.50%

Recent News & Updates

Novo Nordisk (CPH:NOVO B) Has A Rock Solid Balance Sheet

Oct 29
Novo Nordisk (CPH:NOVO B) Has A Rock Solid Balance Sheet

An Intrinsic Calculation For Novo Nordisk A/S (CPH:NOVO B) Suggests It's 38% Undervalued

Oct 11
An Intrinsic Calculation For Novo Nordisk A/S (CPH:NOVO B) Suggests It's 38% Undervalued

Recent updates

Novo Nordisk (CPH:NOVO B) Has A Rock Solid Balance Sheet

Oct 29
Novo Nordisk (CPH:NOVO B) Has A Rock Solid Balance Sheet

An Intrinsic Calculation For Novo Nordisk A/S (CPH:NOVO B) Suggests It's 38% Undervalued

Oct 11
An Intrinsic Calculation For Novo Nordisk A/S (CPH:NOVO B) Suggests It's 38% Undervalued

With EPS Growth And More, Novo Nordisk (CPH:NOVO B) Makes An Interesting Case

Aug 24
With EPS Growth And More, Novo Nordisk (CPH:NOVO B) Makes An Interesting Case

Novo Nordisk (CPH:NOVO B) Could Easily Take On More Debt

Jul 21
Novo Nordisk (CPH:NOVO B) Could Easily Take On More Debt

Novo Nordisk A/S' (CPH:NOVO B) Intrinsic Value Is Potentially 55% Above Its Share Price

Jul 06
Novo Nordisk A/S' (CPH:NOVO B) Intrinsic Value Is Potentially 55% Above Its Share Price

If You Like EPS Growth Then Check Out Novo Nordisk (CPH:NOVO B) Before It's Too Late

May 21
If You Like EPS Growth Then Check Out Novo Nordisk (CPH:NOVO B) Before It's Too Late

We Think Novo Nordisk (CPH:NOVO B) Can Manage Its Debt With Ease

Apr 20
We Think Novo Nordisk (CPH:NOVO B) Can Manage Its Debt With Ease

If You Like EPS Growth Then Check Out Novo Nordisk (CPH:NOVO B) Before It's Too Late

Jan 21
If You Like EPS Growth Then Check Out Novo Nordisk (CPH:NOVO B) Before It's Too Late

Is Novo Nordisk (CPH:NOVO B) A Risky Investment?

Dec 22
Is Novo Nordisk (CPH:NOVO B) A Risky Investment?

A Look At The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Dec 07
A Look At The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Here's Why I Think Novo Nordisk (CPH:NOVO B) Is An Interesting Stock

Oct 23
Here's Why I Think Novo Nordisk (CPH:NOVO B) Is An Interesting Stock

Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Sep 22
Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

A Look At The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Sep 08
A Look At The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Here's Why I Think Novo Nordisk (CPH:NOVO B) Is An Interesting Stock

Jul 24
Here's Why I Think Novo Nordisk (CPH:NOVO B) Is An Interesting Stock

Here's Why Novo Nordisk (CPH:NOVO B) Can Manage Its Debt Responsibly

Jun 24
Here's Why Novo Nordisk (CPH:NOVO B) Can Manage Its Debt Responsibly

Novo Nordisk A/S (CPH:NOVO B) Shares Could Be 27% Below Their Intrinsic Value Estimate

Jun 08
Novo Nordisk A/S (CPH:NOVO B) Shares Could Be 27% Below Their Intrinsic Value Estimate

Should You Be Adding Novo Nordisk (CPH:NOVO B) To Your Watchlist Today?

Apr 12
Should You Be Adding Novo Nordisk (CPH:NOVO B) To Your Watchlist Today?

Here's Why Novo Nordisk A/S' (CPH:NOVO B) CEO Compensation Is The Least Of Shareholders' Concerns

Mar 18
Here's Why Novo Nordisk A/S' (CPH:NOVO B) CEO Compensation Is The Least Of Shareholders' Concerns

Read This Before Buying Novo Nordisk A/S (CPH:NOVO B) For Its Dividend

Mar 08
Read This Before Buying Novo Nordisk A/S (CPH:NOVO B) For Its Dividend

What Can We Conclude About Novo Nordisk's (CPH:NOVO B) CEO Pay?

Feb 24
What Can We Conclude About Novo Nordisk's (CPH:NOVO B) CEO Pay?

Investors Who Bought Novo Nordisk (CPH:NOVO B) Shares Three Years Ago Are Now Up 47%

Feb 13
Investors Who Bought Novo Nordisk (CPH:NOVO B) Shares Three Years Ago Are Now Up 47%

Do Fundamentals Have Any Role To Play In Driving Novo Nordisk A/S' (CPH:NOVO B) Stock Up Recently?

Feb 03
Do Fundamentals Have Any Role To Play In Driving Novo Nordisk A/S' (CPH:NOVO B) Stock Up Recently?

Is There An Opportunity With Novo Nordisk A/S' (CPH:NOVO B) 29% Undervaluation?

Jan 20
Is There An Opportunity With Novo Nordisk A/S' (CPH:NOVO B) 29% Undervaluation?

Is Novo Nordisk (CPH:NOVO B) A Risky Investment?

Jan 05
Is Novo Nordisk (CPH:NOVO B) A Risky Investment?

What Kind Of Shareholders Own Novo Nordisk A/S (CPH:NOVO B)?

Dec 21
What Kind Of Shareholders Own Novo Nordisk A/S (CPH:NOVO B)?

I Built A List Of Growing Companies And Novo Nordisk (CPH:NOVO B) Made The Cut

Dec 09
I Built A List Of Growing Companies And Novo Nordisk (CPH:NOVO B) Made The Cut

Are Insiders Selling Novo Nordisk A/S (CPH:NOVO B) Stock?

Nov 24
Are Insiders Selling Novo Nordisk A/S (CPH:NOVO B) Stock?

Shareholder Returns

NOVO BDK PharmaceuticalsDK Market
7D0.5%0.1%-0.8%
1Y19.5%0.5%-5.1%

Return vs Industry: NOVO B exceeded the Danish Pharmaceuticals industry which returned 0.5% over the past year.

Return vs Market: NOVO B exceeded the Danish Market which returned -5.1% over the past year.

Price Volatility

Is NOVO B's price volatile compared to industry and market?
NOVO B volatility
NOVO B Average Weekly Movement3.8%
Pharmaceuticals Industry Average Movement5.4%
Market Average Movement5.6%
10% most volatile stocks in DK Market11.2%
10% least volatile stocks in DK Market3.3%

Stable Share Price: NOVO B is less volatile than 75% of Danish stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: NOVO B's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
192352,696Lars Jorgensenhttps://www.novonordisk.com

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.

Novo Nordisk A/S Fundamentals Summary

How do Novo Nordisk's earnings and revenue compare to its market cap?
NOVO B fundamental statistics
Market Capkr.2.03t
Earnings (TTM)kr.52.83b
Revenue (TTM)kr.167.20b

38.4x

P/E Ratio

12.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NOVO B income statement (TTM)
Revenuekr.167.20b
Cost of Revenuekr.26.43b
Gross Profitkr.140.77b
Other Expenseskr.87.94b
Earningskr.52.83b

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

Feb 01, 2023

Earnings per share (EPS)23.38
Gross Margin84.19%
Net Profit Margin31.59%
Debt/Equity Ratio33.9%

How did NOVO B perform over the long term?

See historical performance and comparison

Dividends

1.2%

Current Dividend Yield

48%

Payout Ratio